Screener
Boston Scientific BSX Endoscopy — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Boston Scientific in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 6:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000885725-26-000033
| Businesses | Three Months Ended March 31, 2026 / U.S. | Three Months Ended March 31, 2026 / Int'l | Three Months Ended March 31, 2026 / Total | Three Months Ended March 31, 2025 / U.S. | Three Months Ended March 31, 2025 / Int'l | Three Months Ended March 31, 2025 / Total |
|---|---|---|---|---|---|---|
| Endoscopy | $446 | $290 | $736 | $420 | $253 | $673 |
| Urology | 465 | 182 | 646 | 469 | 165 | 633 |
| Neuromodulation | 236 | 82 | 318 | 204 | 67 | 271 |
| MedSurg | 1,147 | 554 | 1,701 | 1,093 | 484 | 1,577 |
| Interventional Cardiology & Vascular Therapies | 552 | 692 | 1,244 | 467 | 657 | 1,124 |
| Watchman | 462 | 44 | 506 | 390 | 34 | 425 |
| Electrophysiology | 603 | 302 | 905 | 511 | 219 | 730 |
| Cardiac Rhythm Management | 349 | 229 | 578 | 358 | 220 | 578 |
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Boston Scientific's endoscopy — net sales?
- Boston Scientific (BSX) reported endoscopy — net sales of $736M in Q1 2026.
- How has Boston Scientific's endoscopy — net sales changed year-over-year?
- Boston Scientific's endoscopy — net sales increased by 9.4% year-over-year, from $673M to $736M.
- What is the long-term trend for Boston Scientific's endoscopy — net sales?
- Over 4 years (2021 to 2025), Boston Scientific's endoscopy — net sales has grown at a 8.0% compound annual growth rate (CAGR), from $2.14B to $2.92B.
- What does endoscopy — net sales mean?
- This metric represents the total revenue generated from the sale of medical devices and equipment within the endoscopy business unit. It reflects the company's market performance in providing diagnostic and therapeutic tools for gastrointestinal and pulmonary procedures. This revenue stream is a key indicator of the firm's ability to capture market share in minimally invasive procedural technologies.
Ask your AI about Boston Scientific's endoscopy — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude